Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san francisco top stories
5
×
fda
national top stories
new york top stories
san francisco blog main
boston blog main
boston top stories
new york blog main
san diego blog main
san diego top stories
drugs
national
roche
akcea therapeutics
allergan
alnylam pharmaceuticals
andrew fire
billy dunn
biogen
biotech
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cannabidiol
clinical data
companion diagnostic
craig mello
detroit blog main
detroit top stories
dna sequencing
dravet syndrome
drug prices
drug pricing
entrectinib
What
approved
5
×
drug
5
×
medicine
fda
new
data
pharmaceuticals
afternoon
ago
alnylam
alnylam’s
atrophy
battle
cancer
cannabis
daily
deeper
derivative
disease
dna
epilepsy
evrysdi
fatty
fingerprint
form
friday
genetic
gets
going
green
gw
gw’s
history
home
horizon
intended
intercept
known
landmark
lights
Language
unset
Current search:
medicine���s
×
drug
×
approved
×
" san francisco top stories "
×
@xconomy.com
4 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
6 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug